RESUMEN
Narcotic analgesics have an inhibiting effect on the immunity and that is why their use for pain relief in cancer patients cannot be regarded as adequate. The effect of a new synthetic analgesic tramal (tramal hydrochloride) on the immune system has been studied. Cellular immunity indexes, immunoglobulin level, and phagocytic activity of neutrophils have been determined before treatment and 1 and 2 weeks after the treatment started. The data obtained have shown that tramal does not inhibit the immune system. It has been also noted that pain relief in cancer patients improved the indexes of cellular and humoral immunity.
Asunto(s)
Neoplasias/inmunología , Tramadol/farmacología , Adulto , Anciano , Formación de Anticuerpos , Humanos , Inmunidad Celular , Neoplasias Intestinales/inmunología , Intestino Grueso , Neoplasias Laríngeas/inmunología , Linfoma no Hodgkin/inmunología , Persona de Mediana Edad , Neoplasias Orofaríngeas/inmunología , Neoplasias del Recto/inmunología , Sarcoma/inmunología , Neoplasias de los Tejidos Blandos/inmunología , Neoplasias Gástricas/inmunología , Factores de Tiempo , Tramadol/administración & dosificación , Neoplasias de la Vejiga Urinaria/inmunologíaRESUMEN
The efficacy of epidural chemical denervation used for the treatment of chronic pain syndrome in cancer patients (clinical stage IV) has been studied at different phases of antinociceptive therapy and also in combination with analgesics. Early use of this technique for the treatment of chronic pain in cancer patients has been recommended and it was concluded that it is more effective in combination with analgesics.